Tremfya Leads TV Pharma Ads in September and Q3
Johnson & Johnson's Tremfya retained its top spot for TV pharma brand ad impressions in September, with a 5.02% impressions share of voice (SOV) and 3.1 billion impressions, following a $32.8 million ad spend.
- Tremfya's ad spend increased by approximately $10 million from August.
- The psoriasis/ulcerative colitis drug garnered most impressions from Univision's ¡Despierta América!
Vicks took the runner-up title, pushing AbbVie's Skyrizi to third place, with a 4.71% impressions SOV and 2.9 billion impressions, primarily through CBS and GMA 3: What You Need to Know, after investing $10.3 million in TV ad spend.
The fall sports season and Spanish language TV played a significant role in TV pharma ad impressions in September.
Author's summary: Tremfya leads TV pharma ads in September.
More News
- Sportsnet | The incredible story of Jonathan Toews return to the NHL – Illegal Curve Hockey
- Staples announces 2025 National Merit Scholarship semifinalists
- Brewers Go Out With a Whimper in NLCS
- “Man Utd are quite convinced…” - Fabrizio Romano reveals “complete” star will leave Old Trafford in 2026
- SoCal freeway shut down for miles due to event involving live ammunition at Camp Pendleton
- EU Updates Age Verification Standards for Minors
- Fabrizio Romano has terrible news for Tottenham midfielder
- Ferrari’s Elkann issues statement – fully backs Vasseur
- Borrower Monitoring, AI Processing, DPA, Verification Tools; Events and Training; Robots Will do What?
- Manchester United’s stance on Kobbie Mainoo leaving Old Trafford in January revealed